Current treatment of metastatic bladder cancer and future directions

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Fleming JD, Cooper JS, Jenson DE et al. AJCC (American Joint Committee on Cancer) Cancer Staging Manuel (5th Edition). Fleming JD, Cooper JS, Jenson DE et al. (Eds). Lippincott-Raven, PA, USA (1997).
   Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–465; discussion 475–467 (2006).
   PubMed Web of Science ®Google Scholar
• Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette–Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol.13(6), 1404–1408 (1995).
   PubMed Web of Science ®Google Scholar
• Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette–Guerin: a multivariate analysis of factors affecting tumor progression. J. Urol.141(1), 22–29 (1989).
   PubMed Web of Science ®Google Scholar
• Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol.158(1), 62–67 (1997).
   PubMed Web of Science ®Google Scholar
• Herr HW. Uncertainty, stage and outcome of invasive bladder cancer. J. Urol.152(2 Pt 1), 401–402 (1994).
   PubMed Web of Science ®Google Scholar
• Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J. Urol.161(2), 449–454 (1999).
   PubMed Web of Science ®Google Scholar
• Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod. Pathol.22(Suppl. 2), S96–S118 (2009).
   PubMedGoogle Scholar
• Samaratunga H, Khoo K. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology45(1), 55–64 (2004).
   PubMed Web of Science ®Google Scholar
• Comperat E, Roupret M, Yaxley J et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology42(7), 650–654 (2010).
   PubMed Web of Science ®Google Scholar
• Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol. Oncol.27(1), 3–7 (2009).
   PubMed Web of Science ®Google Scholar
• Kamat AM, Gee JR, Dinney CP et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J. Urol.175(3 Pt 1), 881–885 (2006).
   PubMed Web of Science ®Google Scholar
• Ghoneim MA, Abdel-Latif M, el-Mekresh M et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J. Urol.180(1), 121–127 (2008).
   PubMed Web of Science ®Google Scholar
• Heudel P, El Karak F, Ismaili N, Droz JP, Flechon A. Micropapillary bladder cancer: a review of Leon Berard Cancer Center experience. BMC Urol.9, 5 (2009).
   PubMedGoogle Scholar
• Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.10(7), 1066–1073 (1992).
   PubMed Web of Science ®Google Scholar
• Roth BJ, Dreicer R, Einhorn LH et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol.12(11), 2264–2270 (1994).
   PubMed Web of Science ®Google Scholar
• Witte RS, Elson P, Bono B et al. Eastern Cooperative Oncology Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol.15(2), 589–593 (1997).
   PubMed Web of Science ®Google Scholar
• de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a Phase II study in non-chemotherapy-pretreated patients. Br. J. Cancer78(10), 1342–1345 (1998).
   PubMed Web of Science ®Google Scholar
• Lorusso V, Pollera CF, Antimi M et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Cooperative Group on Bladder Cancer. Eur. J. Cancer34(8), 1208–1212 (1998).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol.24(21), 3451–3457 (2006).
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Canil CM, Chi KN et al. A Phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother. Pharmacol.67(4), 927–933 (2011).
   PubMed Web of Science ®Google Scholar
• Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.15(7), 2564–2569 (1997).
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol.8(6), 1050–1055 (1990).
   PubMed Web of Science ®Google Scholar
• Stoter G, Splinter TA, Child JA et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J. Urol.137(4), 663–667 (1987).
   PubMed Web of Science ®Google Scholar
• Mead GM, Russell M, Clark P et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br. J. Cancer78(8), 1067–1075 (1998).
   PubMedGoogle Scholar
• Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol.3(11), 1463–1470 (1985).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol.19(10), 2638–2646 (2001).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC Phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer42(1), 50–54 (2006).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol.18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
   PubMed Web of Science ®Google Scholar
• Adamo V, Magno C, Spitaleri G et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology69(5), 391–398 (2005).
   PubMedGoogle Scholar
• Als AB, Sengelov L, Von Der Maase H. Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? Acta Oncol.47(1), 110–119 (2008).
   PubMed Web of Science ®Google Scholar
• Soto Parra H, Cavina R, Latteri F et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized Phase II study. Ann. Oncol.13(7), 1080–1086 (2002).
   PubMed Web of Science ®Google Scholar
• Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol.22(2), 220–228 (2004).
   PubMed Web of Science ®Google Scholar
• deVere White RW, Lara PN Jr, Goldman B et al. A sequential treatment approach to myoinvasive urothelial cancer: a Phase II Southwest Oncology Group trial (S0219). J. Urol.181(6), 2476–2480; discussion 2480–2471 (2009).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Guillem V, Paz-Ares L et al. Phase I–II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J. Clin. Oncol.18(18), 3247–3255 (2000).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, von der Maase H, Mead GM et al. Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J. Clin. Oncol.25(Suppl. 18), LBA5030 (2007).
   Google Scholar
• Galsky MD, Hahn NM, Rosenberg J et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol.12(3), 211–214 (2011).
   PubMed Web of Science ®Google Scholar
• Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer107(3), 506–513 (2006).
   PubMed Web of Science ®Google Scholar
• Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol.7(11), 1748–1756 (1989).
   PubMed Web of Science ®Google Scholar
• Bamias A, Lainakis G, Kastritis E et al. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology73(5–6), 290–297 (2007).
   PubMedGoogle Scholar
• Linardou H, Aravantinos G, Efstathiou E et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Cooperative Oncology Group. Urology64(3), 479–484 (2004).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in ‘unfit’ patients with advanced bladder cancer. Eur. J. Cancer37(17), 2212–2215 (2001).
   PubMed Web of Science ®Google Scholar
• Xu N, Zhang XC, Xiong JP et al. A Phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer7, 98 (2007).
   PubMed Web of Science ®Google Scholar
• De Santis M, Bellmunt J, Mead G et al. Randomized Phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer ‘unfit’ for cisplatin-based chemotherapy: Phase II – results of EORTC study 30986. J. Clin. Oncol.27(33), 5634–5639 (2009).
   PubMed Web of Science ®Google Scholar
• Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized Phase II study. Cancer77(2), 344–351 (1996).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer100(8), 1639–1645 (2004).
   PubMed Web of Science ®Google Scholar
• Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase 2 trial. Eur. Urol.52(1), 134–141 (2007).
   PubMed Web of Science ®Google Scholar
• Carles J, Esteban E, Climent M et al. Gemcitabine and oxaliplatin combination: a multicenter Phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann. Oncol.18(8), 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Ide H, Satou A, Hoshino K et al. Successful management of metastatic urothelial carcinoma with gemcitabine and paclitaxel chemotherapy in a hemodialysis patient. Urol. Int.87(2), 245–247 (2011).
   PubMedGoogle Scholar
• Kaufman DS, Carducci MA, Kuzel TM et al. A multi-institutional Phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol. Oncol.22(5), 393–397 (2004).
   PubMed Web of Science ®Google Scholar
• Albers P, Park SI, Niegisch G et al. Randomized Phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol.22(2), 288–294 (2011).
   PubMed Web of Science ®Google Scholar
• Li J, Juliar B, Yiannoutsos C et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group study. J. Clin. Oncol.23(6), 1185–1191 (2005).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J. Urol.156(5), 1606–1608 (1996).
   PubMedGoogle Scholar
• Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer95(5), 1022–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Culine S, Theodore C, De Santis M et al. A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br. J. Cancer94(10), 1395–1401 (2006).
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Srinivas S, Stadler WM et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large Phase 2 study. Cancer115(18), 4110–4117 (2009).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol.27(27), 4454–4461 (2009).
   PubMed Web of Science ®Google Scholar
• Han KS, Joung JY, Kim TS et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br. J. Cancer98(1), 86–90 (2008).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer112(12), 2671–2675 (2008).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest. New Drugs25(3), 265–270 (2007).
   PubMed Web of Science ®Google Scholar
• Rozzi A, Salerno M, Bordin F, De Marco F, Nicola SD, Lanzetta G. Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a Phase II study. Med. Oncol. doi:10.1007/s12032-010-9749-z (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Kitamura H, Taguchi K, Kunishima Y et al. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a Phase II study of the SUOC group. Cancer Sci.102(6), 1171–1175 (2011).
   PubMedGoogle Scholar
• Albers P, Park SI, Niegisch G et al. Randomized Phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol.22(2), 288–294 (2011).
   PubMed Web of Science ®Google Scholar
• Youssef RF, Mitra AP, Bartsch G Jr, Jones PA, Skinner DG, Cote RJ. Molecular targets and targeted therapies in bladder cancer management. World J. Urol.27(1), 9–20 (2009).
   PubMedGoogle Scholar
• Wright C, Mellon K, Johnston P et al. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer63(6), 967–970 (1991).
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Christodoulou P, Kapralos P et al. The role of p53, MDM2 and c-erbB-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol. Res. Pract.193(11–12), 767–775 (1997).
   PubMed Web of Science ®Google Scholar
• Neal DE, Marsh C, Bennett MK et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet1(8425), 366–368 (1985).
   PubMed Web of Science ®Google Scholar
• Berger MS, Greenfield C, Gullick WJ et al. Evaluation of epidermal growth factor receptors in bladder tumours. Br. J. Cancer56(5), 533–537 (1987).
   PubMed Web of Science ®Google Scholar
• Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer109(10), 2016–2024 (2007).
   PubMed Web of Science ®Google Scholar
• Kruger S, Weitsch G, Buttner H et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int. J. Cancer102(5), 514–518 (2002).
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol.28(8), 1373–1379 (2010).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer115(18), 4090–4095 (2009).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr et al. Results of the Southwest Oncology Group Phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int.105(3), 317–321 (2010).
   PubMed Web of Science ®Google Scholar
• Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A Phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann. Oncol.20(6), 1074–1079 (2009).
   PubMed Web of Science ®Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J. Clin. Oncol.25(16), 2218–2224 (2007).
   PubMed Web of Science ®Google Scholar
• Folkman J, Hochberg M. Self-regulation of growth in three dimensions. J. Exp. Med.138(4), 745–753 (1973).
   PubMed Web of Science ®Google Scholar
• Klagsbrun M, D’Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev.7(3), 259–270 (1996).
   PubMedGoogle Scholar
• Tischer E, Mitchell R, Hartman T et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem.266(18), 11947–11954 (1991).
   PubMed Web of Science ®Google Scholar
• Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J. Urol.166(4), 1275–1279 (2001).
   PubMed Web of Science ®Google Scholar
• Twardowski P, Stadler WM, Frankel P et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology76(4), 923–926 (2010).
   PubMed Web of Science ®Google Scholar
• Hahn NM, Stadler WM, Zon RT et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75. J. Clin. Oncol.29(12), 1525–1530 (2011).
   PubMed Web of Science ®Google Scholar
• Rundle JS, Hart AJ, McGeorge A, Smith JS, Malcolm AJ, Smith PM. Squamous cell carcinoma of bladder. A review of 114 patients. Br J. Urol.54(5), 522–526 (1982).
   PubMedGoogle Scholar
• Serretta V, Pomara G, Piazza F, Gange E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur. Urol.37(1), 85–89 (2000).
   PubMed Web of Science ®Google Scholar
• Khaled HM, Hamza MR, Mansour O, Gaafar R, Zaghloul MS. A Phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma. Eur. J. Cancer36(Suppl. 2), 34–37 (2000).
   PubMed Web of Science ®Google Scholar
• Khaled H, Emara ME, Gaafar RM et al. Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. Urol. Oncol.26(2), 133–136 (2008).
   PubMedGoogle Scholar
• Wright JL, Porter MP, Li CI, Lange PH, Lin DW. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer107(4), 721–728 (2006).
   PubMed Web of Science ®Google Scholar
• Kastritis E, Dimopoulos MA, Antoniou N et al. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res.26(5B), 3865–3869 (2006).
   PubMedGoogle Scholar
• Cheng L, Pan CX, Yang XJ et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer101(5), 957–962 (2004).
   PubMed Web of Science ®Google Scholar
• Pan CX, Zhang H, Lara PN Jr, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev. Anticancer Ther.6(12), 1707–1713 (2006).
   PubMed Web of Science ®Google Scholar
• Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology46(1), 57–63 (2005).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Paz-Ares L, Cuello M et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol.18(3), 522–528 (2007).
   PubMed Web of Science ®Google Scholar
• Vinall RL, Zripoll A, Wang S, Pan CX, Devere White RW. MiR-34a chemo-sensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status. Int. J. Cancer doi:10.1002/ijc.26256 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Henderson PT, Pan CX. Human microdosing for the prediction of patient response. Bioanalysis2(3), 373–376 (2010).
   PubMedGoogle Scholar
• Henderson PT, Li T, He M et al. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int. J. Cancer129(6), 1425–1434 (2011).
   PubMed Web of Science ®Google Scholar
• Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol.2(6), 723–731 (2006).
   PubMedGoogle Scholar
• Chan KS, Espinosa I, Chao M et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA106(33), 14016–14021 (2009).
   PubMed Web of Science ®Google Scholar
• Rink M, Chun FK, Minner S et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int.107(10), 1668–1675 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang H, Aina OH, Lam KS et al. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol. doi:10.1016/j.urolonc.2010.06.011 (2011) (Epub ahead of print).
   Google Scholar
• Lin TY, Zhang H, Wang S et al. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol. Cancer10(1), 9 (2011).
   PubMedGoogle Scholar